{Reference Type}: Case Reports
{Title}: Treatment and economic burden of mucormycosis in China: Case report review and burden estimation.
{Author}: Jian Y;Wang M;Yu Y;Zhuo Y;Xiao D;Lin S;Xuan J;Jian Y;Wang M;Yu Y;Zhuo Y;Xiao D;Lin S;Xuan J;
{Journal}: J Clin Pharm Ther
{Volume}: 47
{Issue}: 7
{Year}: Jul 2022
{Factor}: 2.145
{DOI}: 10.1111/jcpt.13643
{Abstract}: <B>OBJECTIVE: </B>Mucormycosis is an opportunistic fungal infection associated with low incidence but high mortality. Few studies have shown the treatment and disease burden of mucormycosis in China. This study aims at collecting all the reported cases to describe the characteristics and treatment patterns and to assess the economic burden of mucormycosis in China.<BR><B>METHODS: </B>We conducted a literature review of mucormycosis case reports in Chinese patients to summarize the characteristics and treatment patterns of the disease in China. An economic model was built to evaluate the total cost of mucormycosis per person, including direct medical cost, direct non-medical cost and indirect cost.<BR><B>CONCLUSIONS: </B>A total of 676 case reports showed that the most common type of mucormycosis was pulmonary mucormycosis (299/676, 44.2%), and rhinocerebral mucormycosis had the highest case fatality rate (122/185, 68.5%). Among those who used empiric therapies, 48.8% (231/473) did not include anti-mucor drugs; 79.8% (336/421) of the therapies include amphotericin B (AMB) or AMB-lipo after detection of mucormycetes; 98.6% (69/70) of the reported adverse events were associated with AMB and AMB-lipo. The duration of treatment ranged from 90 to 180 days; the length of stay ranged from 22 to 95 days. The average total cost per patient was 166 thousand Chinese Yuan (CNY), of which 93.1% was the direct medical cost (155 thousand CNY).<BR><B>CONCLUSIONS: </B>There are a limited number of antifungal treatment options for mucormycosis in China. This study highlights the critical need to introduce innovative and broader spectrum antifungal drugs with improved safety, better clinical efficacy, easier administration and reduced economic burden to Chinese mucormycosis patients.